Skip to main content
Premium Trial:

Request an Annual Quote

Canopy Biosciences, PercayAI Partner on Omics-Based Drug Discovery

NEW YORK – Newly launched PercayAI said today that it entered into a strategic partnership with Canopy Biosciences to bring augmented intelligence to Canopy's multi-omic and gene expression testing.

PercayAI, which introduced its CompBio product this week, will interface its new technology with Canopy Biosciences' RNA sequencing and NanoString diagnostic tests. CompBio applies artificial intelligence and contextual language processing to help researchers identify relationships within multi-omic datasets to inform drug discovery. 

"Our collaboration with PercayAI will create a powerful union of genomics expertise with cutting-edge analysis solutions to best support scientists in drug development and lead to better patient outcomes," Canopy Biosciences CEO Edward Weinstein said in a statement.

"With CompBio, researchers can explore the biological landscape and rapidly uncover insights in ways not possible with other tools," added PercayAI Chief Commercial Officer Preston Keller said in a statement. "Through our partnership with Canopy Biosciences, scientists will now have access to a powerful and innovative technological service that will help to improve the speed, cost, and success rate of diagnostic and drug development."

PercayAI, spun out of the Genome Technology Access Center at the McDonnell Genome Institute at Washington University School of Medicine in St. Louis, and funded by investment firm Kingdom Capital, launched Monday. Canopy Biosciences is also based in St. Louis.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.